New Malaria Vaccine indicates 100% efficiency

A new vaccine for malaria, called Sanaria PfSPZ-CVac is up to 100% effective when assessed at 10 weeks after last dose, according to the results of a clinical trial.

Malaria parasites are transmitted by the bite of female Anopheles mosquitoes.

The Plasmodium falciparum parasite is responsible for most malaria infections and almost all deaths caused by the disease worldwide.

The researchers injected live malaria parasites into the test subjects, at the same time preventing the development of the disease by adding chloroquine — which has been used to treat malaria for many years.

This enabled the researchers to exploit the behavior of the parasites and the properties of chloroquine.

Once the person is infected, the Plasmodium falciparum parasite migrates to the liver to reproduce.

Malaria only breaks out when the pathogen leaves the liver, entering the bloodstream and going into the red corpuscles, where it continues to reproduce and spread.

As soon as the pathogen enters the bloodstream, however, it can be killed by chloroquine — and the disease cannot break out.